Using single-cell and bulk RNA sequence data, investigators identified four pathway-based GBM subtypes, including a mitochondrial subtype that appears to respond to related inhibitors.
A data monitoring committee said that BMS's immunotherapy plus standard of care would not improve overall survival in MGMT-methylated brain cancer patients.
The Phase I clinical trial will assess Mustang's autologous, IL13Rα2-directed CAR T-cell therapy, MB-101, in patients with leptomeningeal brain tumors.
Researchers used the methylCIBERSORT algorithm to determine the makeup of the tumor immune microenvironment of about 6,000 pediatric central nervous system tumors.
Presentations at the American Society of Clinical Oncology's virtual annual meeting included new findings relevant to both blood- and spinal fluid-based approaches.
A new analysis suggests hypermutation can occur in some chemotherapy-treated gliomas, producing heterogeneous, mutation-rich tumors with poor response to anti-PD-1 treatment.
The FDA and its pediatric oncology drugs advisory committee heard at a recent meeting how the drug is allowing some to live longer than expected, without toxicities.
